RFXANK and metabolic dysfunction-associated steatotic liver disease: A recent genome-wide meta-analysis of MASLD in 4 cohorts of European ancestry participants with electronic health records showed that variant genes such as MAU2 were negatively associated with MASLD-associated signature enzyme (alkaline phosphatase).21 In a comprehensive study involving liver biopsy-confirmed MASLD cases in Japan, genetic variants including GATAD2A were identified as significantly associated with an elevated risk of MASLD (P = 2.3e−08, OR (95%CI) = 1.37 (1.23–1.53)).26 However, the mutations of RFXANK, KIAA0892, and ATP13A1 have not been reported to be associated with MASLD.